Search

Displaying results 3591 - 3600 of 9128 in total
  1. Drug

    Aminophylline

    go.drugbank.com/drugs/DB01223
    ApprovedInvestigational

    Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  2. Drug

    Artesunate

    go.drugbank.com/drugs/DB09274
    ApprovedInvestigational

    [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … [L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.

    Synonyms: AS
  3. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and … Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax.

  4. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. … Structurally, Alglucosidase alfa is a glycoprotein with a calculated mass of 98,008 daltons for the 883 residue mature polypeptide chain, and a total mass of approximately 109,000 daltons, including carbohydrates

  5. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.

  6. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing. … Lanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin.

  7. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine. … CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of

  8. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It is currently under development as topical treatment of psoriasis.

  9. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    AG-702 is a recombinant human heat shock protein also known as stress protein. … It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation.

  10. Drug

    Borage oil

    go.drugbank.com/drugs/DB11238
    Approved

    Borage oil is used as an herbal treatment of skin disorders including eczema, seborrheic dermatitis, and neurodermatitis as well as other inflammatory, cardiovascular and endocrine disorders, although … GLA, which accounts for approximately 24% of the oil, is converted to dihomo-γ-linolenic acid (DGLA) which acts as a precursor to anti-inflammatory mediators such as 1-series prostaglandins and the 3-series